Want to see CTOR full AI Analyst Report?
CTOR Stock Chart & Stats
$1.07
-$0.06(-4.78%)
At close: 4:00 PM EST
$1.07
-$0.06(-4.78%)
Day’s Range― - ―
52-Week Range$0.49 - $5.89
Previous CloseN/A
Volume120.49K
Average Volume (3M)76.71K
Market Cap
$63.26M
Enterprise Value$62.55M
Total Cash (Recent Filing)$2.63M
Total Debt (Recent Filing)$3.80M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume79,851
30 Day Avg. Volume76,714
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue11.15
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$4.00Price Target Upside273.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$20.82M
Bulls Say, Bears Say
Bulls Say
Early LYMPHIR Commercial TractionSustained early uptake across academic and community centers, repeat purchases and expanding formulary presence indicate a developing commercial foundation. Over months this supports durable revenue potential once penetration deepens, aids payor access, and validates field force execution and supply readiness.
Promising Phase 1 Combo Clinical DataClinically meaningful and durable activity in heavily pretreated patients suggests LYMPHIR can be developed beyond CTCL into immuno-oncology combos. If confirmed, this expands addressable indications, supports further clinical investment, bolsters differentiation versus competitors, and underpins longer-term commercial upside.
Secured Financing To Support CommercializationCommitted capital provides multi-quarter operational runway for salesforce growth, market access, manufacturing and medical affairs. This reduces immediate dilution of execution risk and enables staged commercial investment, increasing the likelihood of converting early traction into sustained market penetration.
Bears Say
Pre-revenue With Widening Operating LossesAbsent product-driven revenue, operating losses reflect ongoing R&D and commercial build costs and will persist until meaningful market uptake or new approvals. Continued negative profitability erodes equity, increases financing dependency, and constrains reinvestment flexibility over the medium term.
Weak Cash Generation And Rising Cash BurnMaterial negative operating and free cash flow require external financing to sustain commercialization and clinical programs. Persistent burn increases risk of dilutive financings or onerous debt, compresses strategic optionality, and can force prioritization that slows long-term development plans if capital markets tighten.
Nasdaq Non-compliance And Listing RiskA sustained bid-price deficiency threatens delisting, which would materially impair liquidity, raise cost of capital, and distract management. Even if remedied, the overhang can limit institutional investor interest and complicate future financings, hindering long-term strategic execution.
Citius Oncology News
CTOR FAQ
What was Citius Oncology, Inc.’s price range in the past 12 months?
Citius Oncology, Inc. lowest stock price was $0.49 and its highest was $5.89 in the past 12 months.
What is Citius Oncology, Inc.’s market cap?
Citius Oncology, Inc.’s market cap is $63.26M.
When is Citius Oncology, Inc.’s upcoming earnings report date?
Citius Oncology, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were Citius Oncology, Inc.’s earnings last quarter?
Citius Oncology, Inc. released its earnings results on May 15, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.26.
Is Citius Oncology, Inc. overvalued?
According to Wall Street analysts Citius Oncology, Inc.’s price is currently Undervalued.
Does Citius Oncology, Inc. pay dividends?
Citius Oncology, Inc. does not currently pay dividends.
What is Citius Oncology, Inc.’s EPS estimate?
Citius Oncology, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Citius Oncology, Inc. have?
Citius Oncology, Inc. has 92,981,200 shares outstanding.
What happened to Citius Oncology, Inc.’s price movement after its last earnings report?
Citius Oncology, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -14.019%.
Which hedge fund is a major shareholder of Citius Oncology, Inc.?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (273.83% Upside)
$4.00 (273.83% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.43%
12-Months-Change
Fundamentals
Return on Equity
-99.47%
Trailing 12-Months
Asset Growth
10.13%
Trailing 12-Months
Company Description
Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$4.00
▲(273.83% Upside)
Technical Analysis
Ownership Overview
6.58% Insiders
0.79% Mutual Funds
9.88% Other Institutional Investors
82.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---